TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.1 TEZSPIRE was approved following a Priority Review by the US Food and Drug Administration (FDA) and based on results...

Click to view original post